

# Janneke H H M Van De Wijgert

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8487403/publications.pdf>

Version: 2024-02-01

119  
papers

6,245  
citations

71102

41  
h-index

79698

73  
g-index

135  
all docs

135  
docs citations

135  
times ranked

6821  
citing authors

#	ARTICLE	IF	CITATIONS
1	Feasibility and acceptability of frequent vaginal self-sampling at home by Rwandan women at high risk of urogenital tract infections. <i>Sexually Transmitted Infections</i> , 2022, 98, 58-61.	1.9	3
2	The relationship between hormonal contraception and cervical dysplasia/cancer controlling for human papillomavirus infection: A systematic review. <i>Contraception</i> , 2022, 107, 1-9.	1.5	9
3	Factors Associated With Using the COVID-19 Mobile Contact-Tracing App Among Individuals Diagnosed With SARS-CoV-2 in Amsterdam, the Netherlands: Observational Study. <i>JMIR MHealth and UHealth</i> , 2022, 10, e31099.	3.7	5
4	Detection of SARS-CoV-2 infection in the general population by three prevailing rapid antigen tests: cross-sectional diagnostic accuracy study. <i>BMC Medicine</i> , 2022, 20, 97.	5.5	11
5	Urine and vaginal microbiota compositions of postmenopausal and premenopausal women differ regardless of recurrent urinary tract infection and renal transplant status. <i>Scientific Reports</i> , 2022, 12, 2698.	3.3	16
6	The performance of wearable sensors in the detection of SARS-CoV-2 infection: a systematic review. <i>The Lancet Digital Health</i> , 2022, 4, e370-e383.	12.3	38
7	Thoracic imaging tests for the diagnosis of COVID-19. <i>The Cochrane Library</i> , 2022, 2022, CD013639.	2.8	13
8	Model-based evaluation of school- and non-school-related measures to control the COVID-19 pandemic. <i>Nature Communications</i> , 2021, 12, 1614.	12.8	58
9	Guidance for the design and reporting of studies evaluating the clinical performance of tests for present or past SARS-CoV-2 infection. <i>BMJ</i> , The, 2021, 372, n568.	6.0	18
10	Thoracic imaging tests for the diagnosis of COVID-19. <i>The Cochrane Library</i> , 2021, 2021, CD013639.	2.8	132
11	Treatment Strategies for GLILD in Common Variable Immunodeficiency: A Systematic Review. <i>Frontiers in Immunology</i> , 2021, 12, 606099.	4.8	24
12	A prospective, randomized, single-blinded, crossover trial to investigate the effect of a wearable device in addition to a daily symptom diary for the remote early detection of SARS-CoV-2 infections (COVID-RED): a structured summary of a study protocol for a randomized controlled trial. <i>Trials</i> , 2021, 22, 412.	1.6	15
13	Diagnostic accuracy of rapid antigen tests in asymptomatic and presymptomatic close contacts of individuals with confirmed SARS-CoV-2 infection: cross sectional study. <i>BMJ</i> , The, 2021, 374, n1676.	6.0	73
14	Vaginal bacterial load in the second trimester is associated with early preterm birth recurrence: a nested caseâ€“control study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2021, 128, 2061-2072.	2.3	17
15	Interventions to control nosocomial transmission of SARS-CoV-2: a modelling study. <i>BMC Medicine</i> , 2021, 19, 211.	5.5	21
16	A prospective, randomized, single-blinded, crossover trial to investigate the effect of a wearable device in addition to a daily symptom diary for the Remote Early Detection of SARS-CoV-2 infections (COVID-RED): a structured summary of a study protocol for a randomized controlled trial. <i>Trials</i> , 2021, 22, 694.	1.6	9
17	Reporting guidelines for human microbiome research: the STORMS checklist. <i>Nature Medicine</i> , 2021, 27, 1885-1892.	30.7	170
18	Acceptability and Satisfaction of Contraceptive Vaginal Rings in Clinical Studies: A Systematic Review and Narrative Synthesis. <i>Frontiers in Global Women S Health</i> , 2021, 2, 799963.	2.3	1

#	ARTICLE	IF	CITATIONS
19	Impact of oral metronidazole treatment on the vaginal microbiota and correlates of treatment failure. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 222, 157.e1-157.e13.	1.3	53
20	Lactobacilli-containing vaginal probiotics to cure or prevent bacterial or fungal vaginal dysbiosis: a systematic review and recommendations for future trial designs. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2020, 127, 287-299.	2.3	92
21	Human papillomavirus infection and cervical dysplasia in HIV-positive women. <i>Aids</i> , 2020, 34, 115-125.	2.2	14
22	Authors' reply re: Lactobacilli-containing vaginal probiotics to cure or prevent bacterial or fungal vaginal dysbiosis: a systematic review and recommendations for future trial designs. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2020, 127, 305-305.	2.3	2
23	Thoracic imaging tests for the diagnosis of COVID-19. <i>The Cochrane Library</i> , 2020, 9, CD013639.	2.8	52
24	Thoracic imaging tests for the diagnosis of COVID-19. <i>The Cochrane Library</i> , 2020, 11, CD013639.	2.8	51
25	Impact of delays on effectiveness of contact tracing strategies for COVID-19: a modelling study. <i>Lancet Public Health</i> , The, 2020, 5, e452-e459.	10.0	610
26	Vaginal probiotic adherence and acceptability in Rwandan women with high sexual risk participating in a pilot randomised controlled trial: a mixed-methods approach. <i>BMJ Open</i> , 2020, 10, e031819.	1.9	1
27	Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis. <i>New England Journal of Medicine</i> , 2020, 383, 790-792.	27.0	6
28	Imaging tests for the diagnosis of COVID-19. <i>The Cochrane Library</i> , 2020, , .	2.8	19
29	Intermittent Lactobacilli-containing Vaginal Probiotic or Metronidazole Use to Prevent Bacterial Vaginosis Recurrence: A Pilot Study Incorporating Microscopy and Sequencing. <i>Scientific Reports</i> , 2020, 10, 3884.	3.3	40
30	ECHO: context and limitations. <i>Lancet</i> , The, 2020, 395, e25-e26.	13.7	2
31	ECHO: context and limitations. <i>Lancet</i> , The, 2020, 395, e24.	13.7	2
32	Pathobionts in the Vaginal Microbiota: Individual Participant Data Meta-Analysis of Three Sequencing Studies. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 129.	3.9	28
33	Health-related quality of life in patients with immune mediated inflammatory diseases: A cross-sectional, multidisciplinary study. <i>Clinical Immunology</i> , 2020, 214, 108392.	3.2	13
34	Targeted point-of-care testing compared with syndromic management of urogenital infections in women (WISH): a cross-sectional screening and diagnostic accuracy study. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 658-669.	9.1	42
35	Vaginal dysbiosis and the risk of human papillomavirus and cervical cancer: systematic review and meta-analysis. <i>American Journal of Obstetrics and Gynecology</i> , 2019, 221, 9-18.e8.	1.3	164
36	P024...Targeted point-of-care testing compared to syndromic management of urogenital infections in rwandan women. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
37	Hormonal Contraceptives and the Acquisition of Sexually Transmitted Infections: An Updated Systematic Review. <i>Sexually Transmitted Diseases</i> , 2019, 46, 290-296.	1.7	18
38	The Need for Policy Change Regarding Progestin-Only Injectable Contraceptives. <i>Journal of Women's Health</i> , 2019, 28, 1180-1184.	3.3	4
39	The Evolving Facets of Bacterial Vaginosis: Implications for HIV Transmission. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 219-228.	1.1	188
40	Implementation and evaluation of the Presto combined qualitative real-time assay for Chlamydia trachomatis and Neisseria gonorrhoeae in Rwanda. <i>African Journal of Laboratory Medicine</i> , 2019, 8, 739.	0.6	2
41	Working towards HIV prevention choices for women. <i>Lancet HIV</i> , 2018, 5, e60-e61.	4.7	1
42	High acceptability of a contraceptive vaginal ring among women in Kigali, Rwanda. <i>PLoS ONE</i> , 2018, 13, e0199096.	2.5	14
43	Contraceptive rings promote vaginal lactobacilli in a high bacterial vaginosis prevalence population: A randomised, open-label longitudinal study in Rwandan women. <i>PLoS ONE</i> , 2018, 13, e0201003.	2.5	36
44	A randomised trial of a contraceptive vaginal ring in women at risk of HIV infection in Rwanda: Safety of intermittent and continuous use. <i>PLoS ONE</i> , 2018, 13, e0197572.	2.5	16
45	Prevalence of sexually transmitted infections and bacterial vaginosis among women in sub-Saharan Africa: An individual participant data meta-analysis of 18 HIV prevention studies. <i>PLoS Medicine</i> , 2018, 15, e1002511.	8.4	158
46	Risk of Sexual HIV-1 Transmission: Coinfections Associated with Risk. , 2018, , 1802-1810.		0
47	The global health impact of vaginal dysbiosis. <i>Research in Microbiology</i> , 2017, 168, 859-864.	2.1	130
48	Role of HIV exposure and infection in relation to neonatal GBS disease and rectovaginal GBS carriage: a systematic review and meta-analysis. <i>Scientific Reports</i> , 2017, 7, 13820.	3.3	19
49	A longitudinal analysis of the vaginal microbiota and vaginal immune mediators in women from sub-Saharan Africa. <i>Scientific Reports</i> , 2017, 7, 11974.	3.3	112
50	Vaginal dysbiosis and pre-exposure prophylaxis efficacy. <i>Lancet HIV</i> , 2017, 4, e427-e429.	4.7	2
51	Association of vaginal dysbiosis and biofilm with contraceptive vaginal ring biomass in African women. <i>PLoS ONE</i> , 2017, 12, e0178324.	2.5	16
52	The vaginal microbiome and sexually transmitted infections are interlinked: Consequences for treatment and prevention. <i>PLoS Medicine</i> , 2017, 14, e1002478.	8.4	93
53	The association between ethnicity and vaginal microbiota composition in Amsterdam, the Netherlands. <i>PLoS ONE</i> , 2017, 12, e0181135.	2.5	138
54	Evaluation of Lysis Methods for the Extraction of Bacterial DNA for Analysis of the Vaginal Microbiota. <i>PLoS ONE</i> , 2016, 11, e0163148.	2.5	67

#	ARTICLE	IF	CITATIONS
55	Unique Insights in the Cervicovaginal Lactobacillus iners and L. crispatus Proteomes and Their Associations with Microbiota Dysbiosis. PLoS ONE, 2016, 11, e0150767.	2.5	45
56	A fruitful alliance: the synergy between <i>Atopobium vaginae</i> and <i>Gardnerella vaginalis</i> in bacterial vaginosis-associated biofilm. Sexually Transmitted Infections, 2016, 92, 487-491.	1.9	83
57	Evaluation of an enzymatic <i>Chlamydia trachomatis</i> point-of-care rapid assay in Rwanda: the BioChekSwab Rapid Test: Table A1. Sexually Transmitted Infections, 2016, 92, 430-432.	1.9	6
58	Incorporating microbiota data into epidemiologic models: examples from vaginal microbiota research. Annals of Epidemiology, 2016, 26, 360-365.	1.9	17
59	Adolescent sexual health: time to invest in a healthy future generation. Sexually Transmitted Infections, 2016, 92, 248-249.	1.9	3
60	A DNA tool for early detection of vaginal dysbiosis in African women. Research in Microbiology, 2016, 167, 133-141.	2.1	12
61	Immune Activation in the Female Genital Tract: Expression Profiles of Soluble Proteins in Women at High Risk for HIV Infection. PLoS ONE, 2016, 11, e0143109.	2.5	51
62	A Multi-Country Cross-Sectional Study of Vaginal Carriage of Group B Streptococci (GBS) and Escherichia coli in Resource-Poor Settings: Prevalences and Risk Factors. PLoS ONE, 2016, 11, e0148052.	2.5	61
63	O13.4...Cervicovaginal microbiome dysbiosis is associated with proteome changes related to alterations of the cervicovaginal mucosal barrier. Sexually Transmitted Infections, 2015, 91, A54.1-A54.	1.9	0
64	Twelve-Month Antiretroviral Therapy Suppresses Plasma and Genital Viral Loads but Fails to Alter Genital Levels of Cytokines, in a Cohort of HIV-Infected Rwandan Women. PLoS ONE, 2015, 10, e0127201.	2.5	8
65	Combination Antiretroviral Therapy for HIV in Rwandan Adults: Clinical Outcomes and Impact on Reproductive Health up to 24 Months. AIDS Research and Treatment, 2015, 2015, 1-11.	0.7	1
66	DMPA use and HIV acquisition: time to switch to NET-EN?. Lancet HIV, the, 2015, 2, e263-e264.	4.7	4
67	Cross-Sectional Analysis of Selected Genital Tract Immunological Markers and Molecular Vaginal Microbiota in Sub-Saharan African Women, with Relevance to HIV Risk and Prevention. Vaccine Journal, 2015, 22, 526-538.	3.1	72
68	Hormonal Contraception and the Risk of HIV Acquisition: An Individual Participant Data Meta-analysis. PLoS Medicine, 2015, 12, e1001778.	8.4	170
69	The significance of Lactobacillus crispatus and L. vaginalis for vaginal health and the negative effect of recent sex: a cross-sectional descriptive study across groups of African women. BMC Infectious Diseases, 2015, 15, 115.	2.9	92
70	Correlates of the molecular vaginal microbiota composition of African women. BMC Infectious Diseases, 2015, 15, 86.	2.9	43
71	The ring plus project: safety and acceptability of vaginal rings that protect women from unintended pregnancy. BMC Public Health, 2015, 15, 348.	2.9	15
72	Interpretation, communication, and mechanisms of associations between injectable contraception and HIV risk – Authors' reply. Lancet HIV, the, 2015, 2, e367.	4.7	0

#	ARTICLE	IF	CITATIONS
73	Prevalence, Incidence and Determinants of Herpes Simplex Virus Type 2 Infection among HIV-Seronegative Women at High-Risk of HIV Infection: A Prospective Study in Beira, Mozambique. PLoS ONE, 2014, 9, e89705.	2.5	13
74	The Vaginal Microbiota: What Have We Learned after a Decade of Molecular Characterization?. PLoS ONE, 2014, 9, e105998.	2.5	397
75	Safety and Effectiveness of Combination Antiretroviral Therapy during the First Year of Treatment in HIV-1 Infected Rwandan Children: A Prospective Study. PLoS ONE, 2014, 9, e111948.	2.5	18
76	“Let’s Talk about Sex” A Qualitative Study of Rwandan Adolescents’ Views on Sex and HIV. PLoS ONE, 2014, 9, e102933.	2.5	10
77	<i>Lactobacillus</i> -dominated cervicovaginal microbiota associated with reduced HIV/STI prevalence and genital HIV viral load in African women. ISME Journal, 2014, 8, 1781-1793.	9.8	216
78	HIV Incidence in a Cohort of Women at Higher Risk in Beira, Mozambique: Prospective Study 2009–2012. PLoS ONE, 2014, 9, e84979.	2.5	19
79	Prevalence and Correlates of Bacterial Vaginosis in Different Sub-Populations of Women in Sub-Saharan Africa: A Cross-Sectional Study. PLoS ONE, 2014, 9, e109670.	2.5	85
80	Risk of Sexual HIV-1 Transmission: Coinfections Associated with Risk. , 2014, , 1-10.		0
81	Hormonal contraception decreases bacterial vaginosis but oral contraception may increase candidiasis. Aids, 2013, 27, 2141-2153.	2.2	113
82	Feasibility and Acceptability of a Novel Cervicovaginal Lavage Self-Sampling Device Among Women in Kigali, Rwanda. Sexually Transmitted Diseases, 2013, 40, 552-555.	1.7	18
83	Antiretroviral therapy drug adherence in Rwanda: Perspectives from patients and healthcare workers using a mixed-methods approach. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2013, 25, 1504-1512.	1.2	24
84	Joining and leaving sex work: experiences of women in Kigali, Rwanda. Culture, Health and Sexuality, 2012, 14, 1037-1047.	1.8	21
85	Prevalence and Concordance of HPV, HIV, and HSV-2 in Heterosexual Couples in Kigali, Rwanda. Sexually Transmitted Diseases, 2012, 39, 128-135.	1.7	15
86	Hormonal contraception and the risk of HIV acquisition among women in South Africa. Aids, 2012, 26, 497-504.	2.2	71
87	Molecular and Phylogeographic Analysis of Human Immuno-deficiency Virus Type 1 Strains Infecting Treatment-naïve Patients from Kigali, Rwanda. PLoS ONE, 2012, 7, e42557.	2.5	8
88	HIV Incidence Remains High in KwaZulu-Natal, South Africa: Evidence from Three Districts. PLoS ONE, 2012, 7, e35278.	2.5	41
89	Risk Factor Detection as a Metric of STARHS Performance for HIV Incidence Surveillance Among Female Sex Workers in Kigali, Rwanda. Open AIDS Journal, 2012, 6, 112-121.	0.5	12
90	Anal intercourse among female sex workers in East Africa is associated with other high-risk behaviours for HIV. Sexual Health, 2011, 8, 251.	0.9	34

#	ARTICLE	IF	CITATIONS
91	Methodological Issues in Sampling the Local Immune System of the Female Genital Tract in the Context of HIV Prevention Trials. <i>American Journal of Reproductive Immunology</i> , 2011, 65, 368-376.	1.2	12
92	The risk factor profile of women with secondary infertility: an unmatched case-control study in Kigali, Rwanda. <i>BMC Women's Health</i> , 2011, 11, 32.	2.0	22
93	Intravaginal Practices, Bacterial Vaginosis, and HIV Infection in Women: Individual Participant Data Meta-analysis. <i>PLoS Medicine</i> , 2011, 8, e1000416.	8.4	215
94	Clinical, epidemiological and socio-cultural aspects of infertility in resource-poor settings. Evidence from Rwanda. <i>Afrika Focus</i> , 2011, 24, 106-108.	0.2	1
95	HIV Prevalence and Incidence among Sexually Active Females in Two Districts of South Africa to Determine Microbicide Trial Feasibility. <i>PLoS ONE</i> , 2011, 6, e21528.	2.5	10
96	Clinical, epidemiological and socio-cultural aspects of infertility in resource-poor settings. Evidence from Rwanda. <i>Afrika Focus</i> , 2011, 24, .	0.2	8
97	Treatment of sexually transmitted infections for HIV prevention: end of the road or new beginning?. <i>Aids</i> , 2010, 24, S15-S26.	2.2	142
98	HIV acquisition is associated with prior high-risk human papillomavirus infection among high-risk women in Rwanda. <i>Aids</i> , 2010, 24, 2289-2292.	2.2	32
99	Academic health science systems. <i>Lancet, The</i> , 2010, 375, 1782.	13.7	3
100	Factors affecting transmission of mucosal human papillomavirus. <i>Lancet Infectious Diseases, The</i> , 2010, 10, 862-874.	9.1	131
101	Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy, HIV-negative women. <i>Aids</i> , 2009, 23, 1531-1538.	2.2	77
102	Acceptability of a Carrageenan-Based Candidate Vaginal Microbicide and Matching Placebo: Findings from a Phase II Safety Trial among Women in Chiang Rai, Thailand. <i>Journal of Women's Health</i> , 2009, 18, 1003-1010.	3.3	11
103	Vaginal microbicide adherence biomarkers should be validated. <i>Lancet, The</i> , 2009, 373, 721.	13.7	4
104	Disentangling Contributions of Reproductive Tract Infections to HIV Acquisition in African Women. <i>Sexually Transmitted Diseases</i> , 2009, 36, 357-364.	1.7	117
105	Differentiating normal from abnormal rates of genital epithelial findings in vaginal microbicide trials. <i>Contraception</i> , 2008, 77, 122-129.	1.5	11
106	Bacterial Vaginosis and Vaginal Yeast, But Not Vaginal Cleansing, Increase HIV-1 Acquisition in African Women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 48, 203-210.	2.1	108
107	<i>Trichomonas vaginalis</i> Infection and Human Immunodeficiency Virus Acquisition in African Women. <i>Journal of Infectious Diseases</i> , 2008, 197, 548-554.	4.0	265
108	Vaginal microbicides: the importance of effective distribution, retention and coating of the mucosa. <i>Aids</i> , 2008, 22, 1231-1232.	2.2	3

#	ARTICLE	IF	CITATIONS
109	Vaginal microbicides: moving ahead after an unexpected setback. <i>Aids</i> , 2007, 21, 2369-2376.	2.2	68
110	Is vaginal washing associated with increased risk of HIV-1 acquisition?. <i>Aids</i> , 2006, 20, 1347-1348.	2.2	19
111	Two Methods of Self-Sampling Compared to Clinician Sampling to Detect Reproductive Tract Infections in Gugulethu, South Africa. <i>Sexually Transmitted Diseases</i> , 2006, 33, 516-523.	1.7	40
112	Challenges in Microbicide Trial Design and Implementation. <i>Studies in Family Planning</i> , 2006, 37, 123-129.	1.8	16
113	Phase III microbicide trial methodology: opinions of experienced expanded safety trial participants in South Africa. <i>Sahara J</i> , 2005, 2, 311-319.	0.7	2
114	Microbicide trials for preventing HIV/AIDS in South Africa: Phase II trial participants' experiences and psychological needs. <i>Sahara J</i> , 2004, 1, 78-86.	0.7	19
115	The Need for a "Condoms-Only" Control Group in Microbicide Trials. <i>Epidemiology</i> , 2003, 14, 505.	2.7	3
116	Phase 1 Trial of the Topical Microbicide BufferGel: Safety Results From Four International Sites. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2001, 26, 21-27.	2.1	62
117	Effect of Intravaginal Practices on the Vaginal and Cervical Mucosa of Zimbabwean Women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2000, 24, 62-67.	2.1	8
118	Is audio computer-assisted self-interviewing a feasible method of surveying in Zimbabwe?. <i>International Journal of Epidemiology</i> , 2000, 29, 885-890.	1.9	69
119	Interventions for Sexual Partners of HIV-Infected or High-Risk Individuals. <i>AIDS Prevention and Mental Health</i> , 1994, , 227-242.	0.8	2